Advent International has entered an agreement to purchase Sanofi’s European generics business Zentiva for €1.9bn ($2.2bn).
Advent intends to invest in Zentiva’s operations, production facilities and its research and development (R&D) pipeline, post transaction.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The acquisition will be closed in the fourth quarter of 2018, subject to customary closing conditions.
Based in the US, Advent International is a private equity firm, while Zentiva is a Czech Republic-based provider of generic medicines for various therapeutic areas.
The acquisition will enable the acquirer company to provide patients with high-quality treatments at lower cost.
Eli Lilly has completed the acquisition of ARMO BioSciences for a cash consideration of more than $1.6bn.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe company signed an agreement to purchase all outstanding shares of ARMO at $50 a share in May this year.
Based in the US, Eli Lilly is a pharmaceutical company that provides drugs for cancer treatment, while ARMO, also based in the US, is an immuno-oncology firm that develops drug candidates to treat diseases related to immune system.
The acquisition of ARMO will be a complementary addition to Eli Lilly’s oncology portfolio.
